Tuesday, May 20, 2025
5/20/2025
ID3 regulation of tissue-infiltrating T cells mediating graft-versus-host disease and leukemia rejection - PROJECT SUMMARY Graft-versus-host disease (GVHD) and the sequelae of immunosuppression have been a major barrier to the success of allogeneic hematopoietic stem cell transplantation (allo-HSCT), which can potentially cure hematological cancers such as leukemia, lymphoma and myeloma. GVHD is caused by donor T cells that attack recipient’s non-hematopoietic-lymphoid tissues (non-HLTs), including gastrointestinal (GI) tract, liver and skin. Advanced strategies with more aggressive immunosuppression agents can better control GVHD. Consequently, cancer relapse becomes the major cause of deaths (>50%) in allo-HSCT patients. Persisting alloreactive donor T cells in non-HLTs are known a determinant of GVHD. Indeed, we recently discovered that inhibition of RIPK1/RIPK3 activity in the GI tract reduces both local and systemic GVHD. These observations together with others highlight an urgent need of better defining how GVHD is locally maintained. A hallmark of tissue-infiltrating alloreactive T cells is their capacity to persist and function in response to persistent alloantigens. They show tissue-resident memory T cell features, contain a subset of Tcf1+ progenitor-like T cells (Tcf1+ TPRO) with a great ability to self-renew, and have acquired unique transcriptional programs for local tissue residence. However, the transcriptional regulators that control these processes remain poorly defined. We recently demonstrate that Id3, a transcription regulator important for CD8+ T cell memory response, has dual functions in maintaining alloreactive T cell responses during GVHD. Id3 restrains excessive PD-1 expression and effector differentiation of alloreactive T cells, but promotes the persistence of both Th1 effector T cells and Tcf1+ TPRO cells that infiltrate non-HLTs. Donor T cells lacking Id3 fail to mediate severe GVHD. PD-1 blockade restores the capacity of Id3- ablated donor T cells to induce GVHD. Id3 represses expression of transcription factors, which promote PD-1 transcription and exuberant effector differentiation of activated T cells, but sustains expression of Tcf1 protein, which is required for self-renewal of memory T cells. Building on these findings, we hypothesize that Id3 regulates the formation and maintenance of tissue-infiltrating Tcf1+ TPRO cells that are critical for GVHD maintenance and leukemia control through coordinating the expression of genes engaged in effector differentiation and memory T cell development. Two specific aims are proposed to test this hypothesis. Aim 1 will define the effect of alloreactive Tcf1+ TPRO cells in GVHD maintenance and leukemia control and characterize the central role of Id3 in these T cells. Aim 2 will establish the beneficial effects of ID3-engineered chimeric antigen-receptor (CAR) T cells on eliminating leukemia. Our findings will provide novel molecular insights into biology of tissue-infiltrating alloreactive T cells and lead to novel Id3 targeting-based non-HLT-specific approaches to reduce GVHD without global immune suppression. They will also identify the molecular requirement for CAR T cells to sustain T cell stemness and to resist exhaustion differentiation, thereby enhancing the efficacy of cancer immunotherapy using CAR T cells.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).